No Data
LUYE PHARMA (02186.HK): Rotigotine transdermal patch has been launched in the United Kingdom.
LUYE PHARMA (02186.HK) announced that the group's developed Rotigotine Luye patch has recently been launched in the United Kingdom for the treatment of signs and symptoms of early and late-stage idiopathic Parkinson's disease, as well as for the treatment of moderate to severe idiopathic restless legs syndrome. This product is the first generic version of Neupro to be launched in the United Kingdom, demonstrating bioequivalence with Neupro. Rotigotine Luye has the same dosage specifications as Neupro, and while maintaining the same drug release dose, Rotigotine Luye has a lower carrier.
Luye Pharma Launches Rotigotine Patch in UK, Expands CNS Treatment Portfolio
What is the impact on the domestic Pharmaceutical industry? Many listed companies respond to the USA's tariff on Pharmaceutical.
① Most surveyed listed Pharmaceutical companies are not panicking. Some companies state that if Pharmaceutical tariffs are implemented, they will raise prices to ensure product gross margin; ② Other companies mention that their products are difficult to substitute in the U.S. and are closely monitoring related developments; ③ Industry experts state that if Pharmaceutical tariffs are implemented, compared to Active Pharmaceutical Ingredients and generic drugs, Innovative Drugs may be the least impacted.
China Securities Co.,Ltd.: It is recommended to focus on the new growth and integration opportunities in the Industry.
China Securities Co.,Ltd. remains bullish on high-quality Innovative Drugs companies in 2025 and actively focuses on cutting-edge technologies in pharmaceuticals and medical devices.
LUYE PHARMA (02186.HK): The antidepressant Innovative Drug Ruoxinlin has been approved for marketing in Macau, China.
On April 7th, Gelonghui reported that LUYE PHARMA (02186.HK) announced that its independently developed first-class innovative drug Ruxinlin (Duloxetine Hydrochloride Controlled-Release Tablets) has officially obtained market approval from the Macao Drug Regulatory Authority in China for the treatment of depression. Ruxinlin is the first independently developed chemical innovative drug for the treatment of depression in China, possessing independent intellectual property rights. Preclinical studies show that Ruxinlin has reuptake inhibition effects on serotonin (5-HT), norepinephrine (NE), and dopamine (DA); moreover, PET/CT studies confirm that Ruxinlin can interact with rats and healthy subjects.
Express News | Luye Pharma - Class 1 Innovative Antidepressant Ruoxinlin Approved for Marketing in Macao
